Bolt Biotherapeutics (BOLT) Misses Q3 EPS by 372c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts BOLT Hot Sheet
Join SI Premium – FREE
Bolt Biotherapeutics (NASDAQ: BOLT) reported Q3 EPS of ($3.72). Revenue for the quarter came in at $2.17 million.
For earnings history and earnings-related data on Bolt Biotherapeutics (BOLT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- L.B. Foster (FSTR) Reports In-Line Q3 EPS ; Offers Guidance
- Studio City International Holdings Limited (MSC) Reports Q3 Loss of $0.02
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
